AlphaYou
Overview
Key stats
Fundamentals Sep 9- Open
- $10.78
- 52-wk high
- $14.53
- High
- $11.15
- 52-wk low
- $2.22
- Low
- $10.73
- Prev close
- $10.79
- Mkt cap
- $531.9M
- Volume
- 325.3K
- Beta
- 2.20
- P/S
- 8.1x
- P/B
- 1.6x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -36.6%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net buying.
What insiders are doing
12 trades · 6 mo
Bought$33.8MSold$604K
Activist stakes, short interest & more
2 items
Earnings
Earnings came in 1.6% above what analysts expected.
Earnings per share
-$0.63+1.6%
-$0.64 expected
What the street expects next
Financials
What it sold, what it cost, what was left.
Sep 2025Dec 2025Mar 2026Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $0 |
| Cost of what it sold | $662.0K | $666.0K | $666.0K | — |
| Gross profit | -$662.0K | -$666.0K | -$666.0K | — |
| What it spent | ||||
| Research and development | $17.6M | $17.0M | $19.3M | $21.9M |
| Sales and admin | $5.3M | $4.9M | $5.1M | $5.0M |
| Other operating costs | — | — | -$666.0K | — |
| Total operating expenses | $22.9M | $21.9M | $23.8M | $26.9M |
| What was left | ||||
| Operating profit | -$22.9M | -$21.9M | -$24.4M | -$26.9M |
| Profit before tax | -$21.5M | -$20.8M | -$23.5M | -$25.0M |
| Net profit | -$21.5M | -$20.8M | -$23.5M | -$25.0M |
| EBITDA | -$20.9M | -$20.1M | -$22.9M | -$23.6M |
Technicals
Price structure
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
37balanced
20D volatility
44%annualized
52-week range
$2.22$14.53
20D support
$10.49recent floor
20D resistance
$12.10recent ceiling
Returns
5D -4.3%20D -8.4%60D +26.3%
Price vs moving averages
SMA20 -5.1%SMA50 +1.6%SMA200 +44.3%
Volume pace
0.71xvs prior 20D
News
What the news says
4 articles · 7 days
Coverage is mixed
Tone of tracked coverage
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
Leans bullishSep 2Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares By Investing.com
Leans bearishSep 1Artiva Biotherapeutics CMO Subhashis Banerjee Executes Stock Option Exercise and Sells Shares via 10b5-1 Plan
NeutralSep 1Artiva Biotherapeutics CMO Subhashis Banerjee sells $98,735 in shares
NeutralAug 31